Syngene International, a research, development, and biotech pharmaceutical manufacturing company, has picked Baltimore as the location for its first facility in the United States.
The company said it expects to create 300 jobs and be fully operational by the end of the year, with additional growth anticipated at its 100,000-square-foot biologics manufacturing site.
Headquartered in Bengaluru, India, Syngene International provides research, development, and manufacturing services to pharmaceutical, biotech, nutrition, and other specialty industries worldwide. The company recently acquired the Baltimore biologics manufacturing facility for $36.5 million and plans to invest another $13.5 million in renovations.
The project site will be adapted for monoclonal antibody (mAb) production. It will expand Syngene’s total bioreactor capacity, further supporting mAb production, discovery, and manufacturing. It will also enhance customer supply chain continuity by integrating with Syngene’s existing development and manufacturing sites across India and North America.
“We are very pleased to start our U.S. manufacturing operations in Maryland, with the facility in Bayview, Baltimore,” said Syngene International Managing Director and Chief Executive Officer Peter Bains. “The state-of-the-art biologics facility will complement our India based operations and increase Syngene’s total single-use bioreactor capacity to 50,000L for large molecule discovery, development, and manufacturing services. Maryland is one of the leading biopharma clusters in the U.S. and we are excited to contribute to this vibrant ecosystem and the region’s economy.”
